NCT03742518已完成2 期
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 0.15% & 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 675
- 试验地点
- 3
- 主要终点
- Absolute non-vellus hair count in target area
研究概览
简要总结
This multi-center, randomized, double-blind, placebo-controlled study, conducted in Turkey, will assess the efficacy and safety of topical SM04554 solution (0.15% and 0.25%) applied daily to the scalp of male androgenetic alopecia (AGA) subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Being a Turkish citizen
- •Clinical diagnosis of AGA with Norwood-Hamilton Classification score of 3V or 4
- •Willing to inform females, with whom they may interact, that they are using a topical investigational product and direct contact should be avoided as potential harm to a fetus is unknown
- •Willing and able to attend all study visits
- •Willing to maintain the same hair style and length as at the study start for the duration of the study
- •Willing to not use semi-permanent hair products (e.g., color, texturizers, relaxers) for the duration of the study; daily styling products (e.g., hair gel, mousse, styling spray) will be allowed on non-study visit days
- •Willing to use mild non-medicated shampoo and conditioner for the duration of the study
- •Able to read and understand Turkish
- •Ability to comprehend and willing to sign an informed consent form
排除标准
- •Males who are sexually active, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use condom or whose partner is not using a highly effective method of birth control that includes double barrier, intrauterine device, or hormonal contraceptive combined with single barrier, or abstinence during the study treatment period until 90 days post last dose of study medication
- •Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia
- •Scalp hair loss on the treatment area, due to disease, injury, or medical therapy
- •History of surgical correction (e.g., hair transplantation, scalp reduction) of hair loss on the scalp
- •Previous exposure to SM04554
- •Use of any products (e.g., finasteride, minoxidil, platelet rich plasma, biotin) or devices (e.g., laser light therapy) purported to promote scalp hair growth within 24 weeks prior to the start of the study
- •Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to the start of the study
- •Use of medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within 12 weeks prior to the start of the study
- •Current use of an occlusive wig, hair extensions, or hair weaves
- •History of hypersensitivity or allergies to any ingredient of the study medication
- •Participation in any other investigational drug or medical device trial, which includes or included administration of an investigational study medication or medical device, within 30 days or 5 half-lives of the investigational agent, whichever is longer, prior to the start of the study
- •Use of semi-permanent hair products (e.g., color, texturizers, relaxers) within 30 days prior to the start of the study
- •Use of medicated shampoo or conditioner (medicated shampoo and conditioner refers to any prescription shampoo or conditioner as well as any over-the-counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth) within 30 days prior to the start of the study
- •Subjects who are immediate family members (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study at the investigative site, or are directly affiliated with the study at the investigative site
- •Subjects employed by Samumed, LLC or Samumed Turkey, or any of its affiliates or development partners (i.e., an employee, temporary contract worker, or designee) responsible for the conduct of the study
研究组 & 干预措施
Topical SM04554 0.15% solution
Experimental
Topical SM04554 0.15% solution, once daily for up to 48 weeks
干预措施: Topical SM04554 solution (Drug)
Topical SM04554 0.25% solution
Experimental
Topical SM04554 0.25% solution, once daily for up to 48 weeks
干预措施: Topical SM04554 solution (Drug)
Vehicle
Placebo Comparator
Topical vehicle solution, once daily for up to 48 weeks
干预措施: Topical vehicle solution (Drug)
结局指标
主要结局
Absolute non-vellus hair count in target area
时间窗: Week 48
Absolute non-vellus hair count in target area by phototrichogram (PTG) analysis
次要结局
- Absolute vellus hair count in target area(Weeks 12, 24, 36 and 48)
- Change from baseline in non-vellus hair count in target area(Baseline, and Weeks 12, 24, 36 and 48)
- Absolute total hair count in target area(Weeks 12, 24, 36 and 48)
- Change from baseline in vellus hair count in target area(Baseline, and Weeks 12, 24, 36 and 48)
- Change from baseline in total hair count in target area(Baseline, and Weeks 12, 24, 36 and 48)
- Change from baseline in subject assessment of hair satisfaction(Baseline, and Weeks 6, 12, 18, 24, 30, 36, 42 and 48)
- Absolute non-vellus hair count in target area(Weeks 12, 24, and 36)
- Change from baseline in average non-vellus hair density in target area(Baseline, and Weeks 12, 24, 36 and 48)
- Change from baseline in average non-vellus hair shaft thickness in target area(Baseline, and Weeks 12, 24, 36 and 48)
- Subject assessment of hair growth(Weeks 6, 12, 18, 24, 30, 36, 42 and 48)
研究者
研究点 (3)
Loading locations...
相似试验
终止
2 期
Study of RO6807952 in Patients With Diabetes Mellitus Type 2Diabetes Mellitus Type 2NCT01516476Hoffmann-La Roche2
撤回
3 期
To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)Refractory Status EpilepticusNCT05814523Marinus Pharmaceuticals
已完成
3 期
A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic TherapyDiabetes Mellitus Type 2NCT01871428Hoffmann-La Roche13
Unknown
4 期
Efficacy and Safety of DKF-306 in Patients With Periodontal DiseasesPeriodontal DiseasesNCT05188924Dongkook Pharmaceutical Co., Ltd.158
招募中
2 期
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderGeneralized Anxiety DisorderNCT06701903Intra-Cellular Therapies, Inc.570